Session Title: Refractive
Session Date/Time: Sunday 17/02/2013 | 08:30-11:00
Paper Time: 09:41
Venue: Hall 3
First Author: : D.Holland GERMANY
Co Author(s): : D. Uthoff M. P׌lzl D. Hepper
Purpose:
MIOL implantation at the moment is the most widely used surgical therapy, but it suffers still thes
risk of any intraocular surgery. Some of these options are monovision and PresbyLASIK with the excimer
laser. We investigated the outcomes for simultaneous correction of presbyopia and ammetropia by
biaspherical Presby-LASIK technique called PresbyMax combined with a μ-monovision concept called
PresbyMax.
Setting:
Eye Hospital Bellevue, Kiel, Germany.
Methods:
All presbyopic patients underwent FEMTO-LASIK using the PresbyMAX software delivering biaspheric
multifocal ablation profiles developed by SCHWIND eye-tech-solutions (Kleinostheim, Germany)
and were assessed up to 1 year postoperatively. All Flaps were created by Ziemer LDV Femtolaser (Port,
Switzerland). Mean patient age was 54 years (range: 44-73 years) at the time of surgery. The preoperative
spherical equivalent ranged from -3.75D to +5.25D and the astigmatism from 0.25D to 4.5D. The dominant
eye was targeted with for 0.75D less addition central myopia (in the near vision area) than the nondominant
eye combined with pericentral emmetropia for the central near vision area and the non-dominant
eye had an increased myopic target refraction in the peripheral distance zone.
Results:
The average mean monocular UDVA improved from 0.52logMAR to 0.10logMAR. Mean binocular
UDVA binocular was reached 0.05logMAR postoperatively. The mean CNVA was 0.0logRAD
preoperatively, whereas and the postoperative UNVA was 0.0logRAD too. The mean postoperative
spherical equivalent in the myopic group dominant eyes was +0.02D with cylinder 0.4D astigmatism, and -
0.62D spherical equivalent with 0.4D astigmatism in the non-dominant eyes. In the hyperopic group the
mean postoperative sphere was -0.1dpt and the mean cylinder 0.4dpt.
Conclusions:
In presbyopic patients without symptomatic cataract, but refractive errors PresbyMAX will
decrease the presbyopic symptoms and correct far-distance refraction in the same treatment offering
spectacle-free vision in daily life in most of the treated patients. Further investigation is necessary to
evaluate the overall benefit of this procedure.
Financial Disclosure:
None
